USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
12 Sep 2022 | 02:45 PM GMT

Evidence Requirements for DTx vs Drugs

Anchored by:

Jordan Silberman
Dir of Clinical Analytics & Research
ELEVANCE HEALTH

Participants:

Jordan Silberman Dir of Clinical Analytics & ResearchElevance Health
Jordan Silberman
Dir of Clinical Analytics & ResearchElevance Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Anna-Maria Heidinger Head of Digital Innovation HubDaiichi Sankyo Europe
Anna-Maria Heidinger
Head of Digital Innovation HubDaiichi Sankyo Europe
Ary Deleray Digital Health Business LeaderRoche
Ary Deleray
Digital Health Business LeaderRoche
Emma Carr Co-Founder and Chief Scientific OfficerAmara Therapeutics
Emma Carr
Co-Founder and Chief Scientific OfficerAmara Therapeutics
KJ
Kennetth Joseph DirectorAkili Interactive Labs
KJ
Kennetth Joseph
DirectorAkili Interactive Labs
LD
Leticia Delgado-Herrera Vice President, Medical & Development HeadAstellas
LD
Leticia Delgado-Herrera
Vice President, Medical & Development HeadAstellas
Maike Schmitz Oncology LeadRoX Health GmbH
Maike Schmitz
Oncology LeadRoX Health GmbH
Maxime Champain Search & Evaluation lead, External InnovationBiogen
Maxime Champain
Search & Evaluation lead, External InnovationBiogen
Simon Bock Market Access ManagerTiefenbacher Pharmaceuticals
Simon Bock
Market Access ManagerTiefenbacher Pharmaceuticals
Thyago Ohana Digital Strategy & Capabilities LeadUCB Pharma
Thyago Ohana
Digital Strategy & Capabilities LeadUCB Pharma

About this Meeting

Are you targeting payers as part of your market access strategy? What do you need to know about their evidence requirements for DTx? 

Due to the lack of industry-wide frameworks for DTx evidence, payers' requirements are usually the same as drugs. However, drugs and DTx are very different in nature, and it is often hard to fit DTx into the traditional evidence standards. Even when DTx solutions have proven effective and safe, some payers have refused to continue covering them (for example, Aetna news). This aligns with a point raised in many HealthXL meetings; payers are sometimes more demanding with DTx compared to drugs due to the novelty of these therapies and the lack of knowledge, making it harder for DTx companies to get buy-in. Join this meeting to have a peer-to-peer conversation about: 

  • Clinical evidence payers’ expectations and how to address them efficiently. 
  • What health economics results do DTx companies need to show to convince payers? Most payers look at health economics data and get interested when healthcare costs reduce. What are their expectations from DTx solutions?  
  • Many startups don’t have much evidence at the beginning, but this doesn’t mean they will not be able to work with payers. How do the evidence requirements change according to DTx product maturity? 
  • There is a gap in the DTx industry in terms of criteria on evidence for DTx, hence the standards used are the ones for drugs, which are usually too high for digital solutions. How can the industry work together to provide a guidance/framework widely used by the different stakeholders, including payers?